DUO-E, 2023

Question 1

Study questions for DUO-E?

Answer 1

IO and chemo combo shown activity in dMMR > pMMR, does adding PARPi help with pMMR (better outcomes)?

Question 2

Study design for DUO-E?

Answer 2

Ph III, RCT - 1:1:1 - 3 arms, stratified by MMR status, disease and region
- Carbo/taxol
- Carbo/taxol + durvalumab f/b durvalumab
- Carbo/taxol + durvalumab f/b durvalumab + olaparib

Question 3

Inclusion criteria for DUO-E?

Answer 3

New Stage III or Stage IV or recurrent endometrial cancer (not sarcoma); unable to cure with surgery i/s/o recurrence

Question 4

Results of DUO-E?

Answer 4

No arm with PARPi alone
The PFS with dervalumab (HR 0.71) and dervalumab + olaparib (HR 0.55) improved
Did so consistently across all groups